02 September 2009
In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.
 |
02 September 2009
Iridex has commenced shipment of its IQ 577 laser systems which is designed to treat vision-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma.
|
19 August 2009
OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with glaucoma, has announced the successful completion of clinical trials for their first device with favourable preliminary safety and tolerability.
|
19 August 2009
Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising.
|
19 August 2009
Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced.
|
19 August 2009
NicOx S.A. has signed an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open angle glaucoma and ocular hypertension. As part of this agreement, Pfizer has granted NicOx the right to access and use certain proprietary Xalatan (latanoprost) data.
|
05 August 2009
Alcon Inc. announced it has discontinued development of anecortave acetate for the reduction of IOP associated with glaucoma.
|
05 August 2009
ACUVAIL (Allergan), the ketorolac tromethamine ophthalmic solution, which acts as a treatment for inflammation and pain after cataract surgery has been approved by the FDA.
|
15 July 2009
CSO, which has a background in measuring and analysing the anterior corneal surface has extended its research to the posterior surface with its new device SIRIUS.
|
| 
